ABBV
Strong BuyPremium GrowerAI neutralAbbVie Inc. · Healthcare · United States · $504.8B cap · $1.4B/day traded
$286.74 +0.4% · close 26 Oct · scored 27 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Report expected 29 Oct: the next-year EPS estimate has been little changed over the last 14 weeks.
As of 27 Oct 2026, MoatMap's StockRank for AbbVie Inc. (ABBV) is 86/100, ranked against 24,000+ stocks in 35 markets (Quality 72, Value 34, Momentum 78, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
AbbVie has largely replaced lost Humira revenue with its immunology drugs Skyrizi and Rinvoq and is expanding in neuroscience. It recently won approval for Juvmo in Parkinson's disease and is buying back shares. It is a high-quality, cash-generative business with a reliable dividend. The valuation already reflects much of the immunology success, and US drug pricing policy remains an overhang, so the upside does not look unusually large.
ABOUT ABBVIE INC.
Read
AbbVie Inc. is a global biopharmaceutical company focusing on the research, development, manufacturing, and sales of innovative therapies across immunology, oncology, neuroscience, and other specialty areas. It possesses a robust product pipeline and a portfolio of blockbuster drugs, such as Humira and Skyrizi, driving significant revenue and market share. AbbVie is a leading pharmaceutical innovator known for its strong R&D capabilities and strategic acquisitions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.1B | 54.3B | 56.3B | 61.2B | 1.8% | 64.4B | 67.6B | 73.6B | 9.7% |
| EPS | 6.69 | 2.75 | 2.42 | 2.39 | -29.0% | 3.54 | 3.34 | 3.87 | 27.3% |
| Shares | 1.8B | 1.8B | 1.8B | 1.8B | -0.1% | 1.8B | — | — | — |
| Debt | 63.3B | 59.4B | 67.1B | 67.5B | 2.2% | 70.9B | — | — | — |
| Equity | 17.3B | 10.4B | 3.3B | -3.3B | -56.1% | — | — | — | — |
| Op CF | 24.9B | 22.8B | 18.8B | 19.0B | -8.6% | 19.5B | — | — | — |
| Inv CF | -623.0M | -2.0B | -20.8B | -6.6B | — | — | — | — | — |
| Fin CF | -24.8B | -17.2B | -5.2B | -12.7B | — | — | — | — | — |
Above its 200-day average and 2% below its 52-week high.
Calmer than 81% of stocks we rank over the past year (26% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABBV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ABBV | AbbVie Inc.(you) | $504.8B | 86 | Strong Buy |
| RO.SW | Roche Holding AG | $384.2B | 90 | Strong Buy |
| NOVN.SW | Novartis AG | $295.2B | 85 | Strong Buy |
| AMGN | Amgen Inc. | $237.5B | 90 | Strong Buy |
| AZN.ST | AstraZeneca PLC | $264.5B | 77 | Buy |
| NVO | Novo Nordisk A/S | $172.3B | 83 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $193.5B | 81 | Strong Buy |
| PFE | Pfizer Inc. | $171.2B | 83 | Strong Buy |
| LLY | Eli Lilly and Company | $1.1T | 76 | Buy |
| JNJ | Johnson & Johnson | $635.1B | 62 | Hold |
Peer medians: ROE 2.7% · P/E 23.4x · Gross margin 53.5%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.